```html

Niraparib‑Related Myelosuppression

Overview

Myelosuppression is a decrease in the bone‑marrow’s ability to produce blood cells. When it occurs as a side effect of the PARP inhibitor niraparib, it is usually called “niraparib‑related myelosuppression.” This condition can lead to anemia (low red cells), neutropenia (low neutrophils), and thrombocytopenia (low platelets).

• Who it affects: Adults with advanced ovarian, fallopian‑tube, or primary peritoneal cancer who are prescribed niraparib as maintenance therapy after response to platinum‑based chemotherapy.
• Prevalence: In the pivotal NOVA trial, Grade ≥ 3 (severe) myelosuppression occurred in:
  • Neutropenia – 29% of patients
  • Thrombocytopenia – 25% of patients
  • Anemia – 15% of patients
  Overall, more than 70% of patients experienced some degree of blood‑cell decline during the first year of treatment (Mayo Clinic, 2023).
• Why it matters: Low blood counts increase infection risk, cause fatigue, and can lead to bleeding. Prompt recognition and management help keep patients on therapy and maintain quality of life.

Symptoms

Symptoms stem from the three main blood‑cell lines that can be suppressed.

Anemia (low red blood cells)

• Fatigue or feeling unusually weak
• Dizziness or light‑headedness, especially when standing
• Shortness of breath on exertion
• Pale skin, especially of the inner eyelids
• Rapid heartbeat (palpitations)

Neutropenia (low neutrophils)

• Fever ≥ 100.4 °F (38 °C) without an obvious source
• Chills or rigors
• Frequent infections – especially respiratory, urinary, or skin infections
• Mouth sores or ulcerations that heal slowly

Thrombocytopenia (low platelets)

• Easy bruising or bruises that appear spontaneously
• Nosebleeds that last longer than 10 minutes
• Bleeding gums or prolonged bleeding from minor cuts
• Blood in urine or stool (dark/black stools)
• Petechiae – tiny red or purple spots on the skin, often on the lower legs

General warning signs

• Unexplained weight loss
• Persistent fatigue that interferes with daily activities
• Sudden onset of severe weakness or fainting

Causes and Risk Factors

Primary cause – Niraparib inhibits poly (ADP‑ribose) polymerase (PARP), an enzyme involved in DNA repair. While this mechanism selectively kills cancer cells with defective homologous recombination, it also affects rapidly dividing normal cells, including hematopoietic stem cells in the bone marrow.

Risk factors that increase the likelihood or severity of myelosuppression

• Baseline blood counts: Patients who start niraparib with low normal neutrophils, platelets, or hemoglobin are at higher risk (CDC, 2022).
• Body weight ≤ 77 kg (≈ 170 lb): The FDA‑approved starting dose of 300 mg daily is reduced to 200 mg for patients ≤ 77 kg because lower body mass correlates with higher drug exposure.
• Renal impairment: Decreased clearance can increase drug levels.
• Prior chemotherapy: Cumulative marrow toxicity from platinum agents or taxanes predisposes to deeper drops.
• Concurrent myelosuppressive drugs: E.g., anti‑cancer agents, certain antibiotics (chloramphenicol), or immunosuppressants.
• Genetic factors: Polymorphisms in drug‑metabolizing enzymes (e.g., CYP3A4) may affect niraparib exposure.

Diagnosis

Diagnosis is based on a combination of clinical presentation, medication history, and laboratory testing.

Laboratory tests

• Complete blood count (CBC) with differential: Obtained at baseline, then typically every 2–4 weeks for the first three months, then monthly. A drop below the following thresholds suggests Grade ≥ 3 myelosuppression (CTCAE v5.0):
  • Neutrophils < 500 cells/µL
  • Platelets < 25 × 10⁹/L
  • Hemoglobin < 8 g/dL
• Reticulocyte count: Helps differentiate marrow production problems from peripheral loss.
• Peripheral smear: Evaluates morphology for clues to other marrow disorders.

Additional assessments (if indicated)

• Bone‑marrow biopsy – rarely needed unless counts fail to recover or alternative pathology is suspected.
• Infection work‑up – blood cultures, urinalysis, or chest imaging when fever or infection signs appear.

Treatment Options

Management aims to protect the patient, allow bone‑marrow recovery, and keep cancer therapy on track.

Medication adjustments

• Dose reduction: Most common first step. For Grade ≥ 2 neutropenia or thrombocytopenia, reduce niraparib by 100 mg (e.g., from 300 mg to 200 mg). If counts don’t recover, consider another 100‑mg reduction or temporary interruption.
• Treatment interruption: Hold niraparib until blood counts return to ≥ 75 % of baseline, then restart at a lower dose.
• Growth‑factor support:
  • Granulocyte‑colony stimulating factor (G‑CSF, e.g., filgrastim, pegfilgrastim) for persistent neutropenia or febrile neutropenia.
  • Erythropoiesis‑stimulating agents (ESA) for symptomatic anemia, after weighing thrombotic risk.

Transfusion therapy

• Red‑cell transfusion: For symptomatic anemia (Hb < 8 g/dL) or when fatigue interferes with daily life.
• Platelet transfusion: If platelets < 10 × 10⁹/L or bleeding occurs at higher counts.

Supportive care & lifestyle measures

• Iron, vitamin B12, or folate supplementation if deficiencies are identified.
• Antimicrobial prophylaxis (e.g., fluoroquinolones, antifungals) for patients with prolonged neutropenia < 500 cells/µL lasting > 7 days (NIH guidelines).
• Strict hand hygiene and avoidance of crowded places during periods of neutropenia.

When to consider alternative therapy

If myelosuppression is recurrent despite dose reductions, clinicians may switch to another maintenance agent (e.g., olaparib, bevacizumab) after multidisciplinary discussion.

Living with Niraparib‑Related Myelosuppression

Proactive self‑care can reduce complications and keep you active.

Monitoring at home

• Keep a personal log of CBC results, medication doses, and any symptoms.
• Use a thermometer and record any fever ≥ 100.4 °F (38 °C) promptly.
• Schedule labs on the same day each month to detect trends early.

Nutrition & hydration

• Prioritize iron‑rich foods (lean red meat, beans, fortified cereals) and vitamin C to enhance absorption.
• Stay well‑hydrated – aim for ≥ 2 L of water daily, unless fluid restriction is ordered.
• Consider small, frequent meals if fatigue limits appetite.

Activity recommendations

• Gentle aerobic exercise (walking, stationary cycling) 3‑5 times per week improves stamina without over‑taxing the marrow.
• Avoid high‑impact sports or contact activities while platelet counts are < 50 × 10⁹/L.

Infection‑prevention tips

• Wash hands with soap for ≥ 20 seconds before eating or after using the restroom.
• Wear a mask in healthcare settings and during community outbreaks of respiratory viruses.
• Keep up‑to‑date on vaccinations (influenza, COVID‑19, pneumococcal), but discuss timing with your oncologist because live vaccines are contraindicated during severe neutropenia.

Emotional well‑being

• Join a support group for patients on PARP inhibitors; shared experiences reduce isolation.
• Consider counseling or mindfulness apps if anxiety about blood counts becomes overwhelming.

Prevention

While myelosuppression cannot be completely avoided, several strategies lower the risk:

• Baseline assessment: Thorough CBC and renal‑function labs before initiating niraparib.
• Weight‑based dosing: Use the FDA‑recommended 200 mg daily dose for patients ≤ 77 kg.
• Early dose modifications: Promptly reduce dose if CBC trends show a ≥ 15 % drop from baseline, even before reaching Grade 2.
• Prophylactic G‑CSF: Consider for patients with prior severe neutropenia or those receiving concomitant myelosuppressive agents.
• Lifestyle hygiene: Hand washing, avoiding raw or undercooked foods, and limiting exposure to sick contacts.
• Regular communication: Report new symptoms immediately; schedule lab appointments and keep them.

Complications

If myelosuppression is not recognized or managed:

• Febrile neutropenia: A medical emergency with > 38 °C fever and low neutrophils, carries a mortality of up to 10 % without prompt antibiotics (CDC, 2022).
• Severe anemia: May lead to cardiac strain, worsening heart failure, or syncope.
• Life‑threatening bleeding: Intracranial or gastrointestinal hemorrhage can occur when platelets fall below 10–20 × 10⁹/L.
• Treatment discontinuation: Persistent myelosuppression may force clinicians to stop niraparib, potentially compromising cancer control.
• Secondary infections: Opportunistic pathogens (e.g., *Pneumocystis jirovecii*) can cause pneumonia in prolonged neutropenia.

When to Seek Emergency Care

References

• Mayo Clinic. “Niraparib side effects.” Updated 2023. https://www.mayoclinic.org
• Novartis. “Niraparib (Zejura) prescribing information.” 2022.
• National Cancer Institute. “Myelosuppression.” Accessed 2024. https://www.cancer.gov
• CDC. “Guidelines for the prevention and treatment of neutropenic fever.” 2022.
• NIH. “Management of chemotherapy‑induced neutropenia.” 2023.
• Cleveland Clinic. “Anemia in cancer patients.” 2023.
• World Health Organization. “Pharmacovigilance of PARP inhibitors.” 2024.

```